1. Zhu X, Ye H, Fu Y. The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine 2016; 95: e4193. [
DOI:10.1097/MD.0000000000004193] [
PMID] [
PMCID]
2. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update 2017; 23: 211-220. [
DOI:10.1093/humupd/dmw047] [
PMID]
3. Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steril 2017; 108: 505-512. [
DOI:10.1016/j.fertnstert.2017.06.017] [
PMID]
4. Huang CY, Chen GY, Shieh ML, Li HY. An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders. Reprod Biol Endocrinol 2018; 16: 18. [
DOI:10.1186/s12958-018-0335-0] [
PMID] [
PMCID]
5. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018; 33: 229-237. [
DOI:10.1093/humrep/dex367] [
PMID]
6. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine 2016; 95: e2939. [
DOI:10.1097/MD.0000000000002939] [
PMID] [
PMCID]
7. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. [
DOI:10.1093/humrep/deh098] [
PMID]
8. Eftekhar M, Rahsepar M, Rahmani E. Effect of progesterone supplementation on natural frozen-thawed embryo transfer cycles: a randomized controlled trial. Int J Fertil Steril 2013; 7: 13-20.
9. Gardner DK, Weissman A, Howles CM, Shoham Z. Textbook of assisted reproductive techniques: laboratory and clinical perspectives. UK: CRC press; 2016. [
DOI:10.1201/9781439813942]
10. Kosmas IP, Kolibianakis EM, Devroey P. Association of estradiol levels on the day of hCG administration and pregnancy achievement in IVF: a systematic review. Hum Reprod 2004; 19: 2446-2453. [
DOI:10.1093/humrep/deh473] [
PMID]
11. Serna J, Cholquevilque JL, Cela V, Martínez-Salazar J, Requena A, Garcia-Velasco JA. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. Fertil Steril 2008; 90: 2190-2195. [
DOI:10.1016/j.fertnstert.2007.10.021] [
PMID]
12. Joo BS, Park SH, An BM, Kim KS, Moon SE, Moon HS. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner. Fertil Steril 2010; 93: 442-426. [
DOI:10.1016/j.fertnstert.2009.02.066] [
PMID]
13. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104: 62-70. [
DOI:10.1016/j.fertnstert.2015.03.022] [
PMID]
14. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet 2018; 298: 663-671. [
DOI:10.1007/s00404-018-4856-8] [
PMID]